Pathway Diagnostics has released the SensiTrop II assay, a new version of its SensiTrop assay that combines molecular heteroduplex tracking assay technology with molecular sequencing to determine the co-receptor tropism status of HIV-infected patients.
The company performs the assay in its CLIA-certified laboratory on samples received from national reference laboratories in the US and from Delphic Diagnostics in Europe.
Pathway said that it recently compared the performance of SensiTrop II with Monogram Biosciences’ Trofile assay using 100 HIV treatment-experienced patient samples provided by Pfizer and previously tested by the Trofile assay. According to the company, SensiTrop II classified 41 samples as dual/mixed (D/M) tropic, while Trofile classified nine of these samples as R5-tropic. This number that is similar to the misclassification rate in Maraviroc's phase III data, Pathway said.
SensiTrop II is available through national reference laboratories and is also being used in CCR5 compound clinical trials, the company said.